ASO Drug Targets ALS and FTD Neuronal Hyperexcitability
Northwestern researchers found a way to calm overactive neurons and restore neuronal activity, potentially slowing disease progression.
A recent Northwestern University study used patient nervous tissue and lab-grown human neurons to investigate how the disease protein TDP-43 contributes to overactive nerve cells in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
- ALS affects about 350,000 people worldwide, causing progressive weakness and muscle atrophy by attacking the spinal cord’s motor neurons.
- The study's findings explain why nerve cells overfire in ALS and FTD and highlight a promising new drug to slow or prevent disease progression.
No direct quote available in the text.
Author's summary: Researchers calm overactive neurons in ALS and FTD.
More News
- JUST IN: Kelly Olynyk has been waived by the San Antonio Spurs
- Kelly Osbourne — Instagram Snapshot
- Kelly Massol : « J’ai réalisé 40% de mon ambition »
- Lightning vs. Islanders Prediction, Odds, Picks - Dec. 6
- Guadeloupean artist Kelly Sinnapah Mary wins French art prize at Art Basel Miami Beach
- Spurs' Luke Kornet out Friday
- Game Preview: Islanders vs Lightning
- Jay Kelly cast guide: All on which characters George Clooney, Adam Sandler and Laura Dern play in the film
- NBA: Spurs at Timberwolves
- Kelly Vedovelli révèle sa vie amoureuse